Newport's Isoprinosine
Executive Summary
Results from U.S./U.K. study in AIDS-related complex patients with T-helper cell depletion do not support efficacy of the agent and will not be used to seek approval of the drug, Newport reports. The firm is discontinuing the U.S./U.K. study, but says it still may seek approval of the drug for ARC if results from an ongoing Scandanavian or Australian study are more promising. Results from the Scandanavian study are expected in early 1989. The Australian study is a long-term trial in HIV-positive patients without symptoms of immunodeficiency....
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.